A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

NCT01206517 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Bipolar I Disorder

Interventions

DRUG: Asenapine 2.5 mg
DRUG: Asenapine 5 mg
DRUG: Asenapine 10 mg

Sponsor

Organon and Co